Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06485843 · ClinicalTrials.gov registry record · Phase 2
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
A Phase 2 study of Osteoarthritis and Osteoarthritis, Knee, sponsored by Ageless Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06485843: Recruiting Phase 2 study of Osteoarthritis and Osteoarthritis, Knee, sponsored by Ageless Biotech.
NCT06485843 is a Phase 2 study of Osteoarthritis and Osteoarthritis, Knee that is actively recruiting participants, run by Ageless Biotech. The registered enrollment target is 400 participants, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06485843, a Phase 2 study of Osteoarthritis and Osteoarthritis, Knee, is actively recruiting participants, sponsored by Ageless Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
Primary Outcome
Presence of adverse events in less than 5% of the study population, as a measure of safety
Conditions Studied
Interventions
- DRUG OA-SYS
Study Locations (1)
Nevada
- Orthopedic & Sports Medicine Institute of Las Vegas - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06485843 shows while recruiting
NCT06485843 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which OA-SYS is the first listed.
NCT06485843 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT06485843 about?
NCT06485843 is a clinical study titled "An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint". This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.
What is the current status of trial NCT06485843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2025-05-21. Estimated completion is 2028-12-31.
What conditions does trial NCT06485843 study?
This clinical trial studies the following conditions: Osteoarthritis, Osteoarthritis, Knee.
What interventions are being tested in trial NCT06485843?
The interventions under investigation include: OA-SYS (DRUG).
Who is sponsoring clinical trial NCT06485843?
This trial is sponsored by Ageless Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06485843 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06485843's enrollment target sits among peer trials
400 31st of 135 higher than 105 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Adductor Canal Block
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI